Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Aug 5, 2025, after the close
10-Q filed Aug 5, 2025, 36 days after period end · 0001396814-25-000102
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $181.10M | $178.02M | $169.47M | $169.41M |
| Net Income | -$4.85M | $18.89M | $25.76M | $19.88M |
| EPS Diluted |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| -$0.11 |
| $0.39 |
| $0.51 |
| $0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.